ASH 2021

Part I: Pola-R-CHP - possible new standard in 1st line?

Prevention of CNS relapse after R-CHOP

HD-MTX does not lower SCNS rates in high-risk patients

pola-R-CHP vs. R-CHOP: a new standard?

Axi-cel - new standard for r/r LBCL patients?

Tisa-cel - new CAR-T option for R/R aNHL

Axi Cel: un nuovo standard nel DLBCL recidivato o…

pola-R-CHP vs. R-CHOP: Neuer Standard?

La prevenzione della recidiva a carico del sistema…

Part II: The white elephant in the room - BTKi

Next generation BTKI Pirtobrutinib

HiDAC-containing induction before ASCT substantially…

Low-dose lenalidomide added to rituximab maintenance in…

Glofitamab SUD as monotherapy after Gpt induced high…

Pirtobrutinib - promising agent moving forward

Maintenance with Rituximab-Lenalidomid (R2)

Focus on maintenance is critical in MCL

Pirtobrutinib shows promising efficacy and safety in…

Pirtobrutinib: Neuer, nicht-kovalenter BTKi

Ruolo del mantenimento con R2 nel linfoma mantellare

Rituximab-Lenalidomid Erhaltungstherapie (R2)

Añadir lenalidomida a dosis bajas a rituximab en el…

Eficacia y seguridad de brexu-cel en pacientes con LCM…

Pirtobrutinib es eficaz y seguro en pacientes muy…

Part II: Bi-specific antibodies as an attractive agent

First-line options and RM

Novel immunotherapy approaches to R/R follicular…

MRD monitoring in follicular lymphoma is extremely…

Ruolo del monitoraggio della malattia minima residua…

Mosunetuzumab + Lenalidomid beim r/r FL

Part II: More data to wait for

BTKi as new option for untreated CLL/SLL patients

NDMM: On the way to cure?

The immunotherapy tsunami continues - bispecific…

The immunotherapy tsunami continues - CAR-T cells

Positive results for high-risk myeloma from the UK

Triplet therapie in elderly patients

Quadruple therapy - the treatment of choice in NDMM

No benefit for elotuzumab in NDMM

Quadruple regimens for NDMM

PFS separation in the Griffin trial

Isatuximab + RVd erfogreich, Elotuzumab nicht

PFS separation in the Griffin trial

Quadrupletts Dara-VTd bzw. Dara-RCd erste Optionen bei…

talquetamab & cevostamab: bispecific antibodies beyond…

Personalized medicine with venetoclax

Elranatamab - a new bispecific antibody in RRMM

TAK-573 - a really new mechanism of treatment in…

cilta-cel: early, deep and durable responses in heavily…

cilta-cel highly effective in heavily pretreated…

Is CAR-T cell treatment better in heavly pretreated…

Update on bispecific antibody teclistamab

Not another BCMA drug

KRd consolidation reverses PET positivity in 1/3 of the…

TAK-573 - a really new mechanism of treatment in…

cilta-cel: frühes, tiefes, lang anhaltendes Ansprechen…

New bispecific antibodies and CAR-T cells for RRMM…

Talquetamab und Cevostamab: Neue bispezifische Ak…

CAR-T oder bispezifische MoAk in der Rezidivtherapie -…

KRd consolidation reverses PET-positivity in 1/3 of the…

Bispezifischer Antikörper Teclistamab beim r/r MM

MGUS and COVID-19 risk

Myeloma precursor disease 2021

New reference values for light chains in multiple…

Myeloma precurser disease 2021